Nola E. Masterson is Director at REPROS THERAPEUTICS INC. (RPRX). They have made 13 open-market trades across 3 companies since 2006, most recently 2025-01-01.
CIK 0001305231
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
10 open-market purchases totalling $25K since 2006, against 3 sales. Across 8 scored buys the stock is up 0.3% at ninety days, and 1.3 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 88% | 100% | 88% |
| Avg Move | +13.3% | +2.8% | +0.3% |
| Alpha | -26.7% | +1.9% | -1.3% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ZIVO | BUY | 2022-12-19 | 2022-12-21 | $2.64 | $792 | -5.7% | +14.0% | +19.3% |
| ZIVO | BUY | 2021-06-02 | 2021-06-04 | $4.99 | $2K | +1.1% | +1.4% | -23.5% |
| RPRX | SELL | 2016-11-21 | 2016-11-23 | $1.95 | $6K | +18.4% | +1.1% | +1.1% |
| RPRX | BUY | 2014-09-15 | 2014-09-17 | $14.34 | $3K | +18.4% | +1.1% | +1.1% |
| RPRX | BUY | 2010-07-07 | 2010-07-09 | $0.30 | $2K | +18.4% | +1.1% | +1.1% |
| RPRX | BUY | 2010-06-24 | 2010-06-25 | $0.41 | $2K | +18.4% | +1.1% | +1.1% |
| GNBT | BUY | 2009-11-13 | 2009-11-16 | $0.49 | $5K | N/A | N/A | N/A |
| GNBT | SELL | 2009-11-12 | 2009-11-13 | $0.50 | $25K | N/A | N/A | N/A |
| GNBT | SELL | 2009-10-19 | 2009-10-19 | $0.69 | $2K | N/A | N/A | N/A |
| RPRX | BUY | 2008-10-14 | 2008-10-15 | $7.00 | $3K | +18.4% | +1.1% | +1.1% |
| GNBT | BUY | 2008-03-11 | 2008-03-12 | $1.06 | $3K | N/A | N/A | N/A |
| RPRX | BUY | 2008-02-04 | 2008-02-06 | $8.60 | $4K | +18.4% | +1.1% | +1.1% |
| RPRX | BUY | 2006-11-27 | 2006-11-29 | $5.59 | $559 | +18.4% | +1.1% | +1.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.